Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
| Status: | Archived |
|---|---|
| Conditions: | Ovarian Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2008 |
Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary
The purpose of this study is to determine if the combination of bevacizumab and pemetrexed
have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at
progression and survival at 6 months.
Patients will be treated with pemetrexed 500 mg/m2 IV and Bevacizumab 15 mg/kg IV every 3
weeks.The patient is treated indefinitely until side effects are deemed severe by the
investigator or until progression. Disease progression is measured every 6 weeks using
RECIST criteria.
We found this trial at
2
sites
Columbia Presbyterian Med Ctr On January 1, 1998, The New York Hospital publicly announced its...
Click here to add this to my saved trials
Washington University Washington University creates an environment to encourage and support an ethos of wide-ranging...
Click here to add this to my saved trials